Drotaverine hydrochloride
{logo}
This medicine should always be used exactly as described in this package leaflet for the patient or as directed by a doctor or pharmacist.
No-Spa Comfort is a spasmolytic medicine that reduces pain (painful spasms) in the abdominal and pelvic organs, i.e., the digestive tract (stomach and intestines), bile and urinary tract, and in women, also the reproductive tract.
No-Spa Comfort contains drotaverine hydrochloride as the active substance. This substance is used for smooth muscle spasms of both nervous and muscular origin, most often manifested by abdominal pain. The spasmolytic action of drotaverine does not depend on the type of innervation and the location of smooth muscles (digestive tract, urinary and reproductive system, circulatory system, and bile ducts).
The medicine is metabolized in the liver and excreted mainly in the urine and to a lesser extent through the digestive tract.
of the pylorus and cardia of the stomach, irritable bowel syndrome, spastic constipation and intestinal bloating, pancreatitis
Before starting to use No-Spa Comfort, the patient should discuss it with their doctor.
Caution should be exercised when using No-Spa Comfort:
The medicine should not be used during labor.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Caution should be exercised when administering No-Spa Comfort with levodopa (a medicine used in Parkinson's disease) due to the reduced anti-Parkinsonian effect and increased tremors and stiffness.
The medicine can be taken with or without food.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor before using this medicine.
Drotaverine crosses the placenta.
The medicine should not be used during labor.
It is not recommended to use this medicine during breastfeeding.
At therapeutic doses, the medicine does not affect the ability to drive vehicles or operate machinery when taken orally.
In case of dizziness, the patient should avoid potentially hazardous activities, such as driving or operating machinery.
Each tablet contains 52 mg of lactose monohydrate, 0.007 mg of tartrazine (E 102), and 0.245 mg of soy lecithin.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
Due to the presence of tartrazine (E 102), the medicine may cause allergic reactions.
Due to the presence of soy lecithin, the medicine should not be used in case of known hypersensitivity to peanuts or soy.
This medicine should always be used exactly as described in this package leaflet for the patient or as directed by a doctor, pharmacist, or nurse. In case of doubt, the patient should consult their doctor, pharmacist, or nurse.
The medicine is administered orally.
Adults:
Daily dose: 120 to 240 mg, in 2 to 3 divided doses.
Children:
Clinical trials have not been conducted in children. Caution should be exercised when using No-Spa Comfort in children from 6 years of age.
In case of necessity to use No-Spa Comfort in children:
If after 10 days there is no improvement or the patient feels worse, they should contact their doctor.
In case of taking a higher dose of the medicine than recommended, the patient should immediately consult their doctor or pharmacist.
In case of missing a dose of the medicine, the patient should take it as soon as possible, unless it is close to the time of the next dose.
The patient should not take two doses of the medicine at the same time or at short intervals.
In case of any further doubts about using the medicine, the patient should consult their doctor or pharmacist.
Like all medicines, No-Spa Comfort can cause side effects, although not everybody gets them.
Rare(may affect up to 1 in 1000 people):
Frequency not known(cannot be estimated from the available data):
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Post-Marketing Surveillance of Medicinal Products, Medical Devices, and Biocidal Products, ul. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The medicine should not be used after the expiry date stated on the carton or blister.
The expiry date refers to the last day of the month.
Store in a temperature below 25°C. Store in the original package to protect from light.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.
The pack contains 20, 30, 40, or 60 coated tablets.
Blisters of PA/Al/PVC/Al or PVC/Al foil in a cardboard box.
Not all pack sizes may be marketed.
Marketing authorization holder
Opella Healthcare Poland Sp. z o.o.
ul. Marcina Kasprzaka 6
01-211 Warsaw
Manufacturer
Opella Healthcare Poland Sp. z o. o.
Branch in Rzeszów
ul. Lubelska 52
35-233 Rzeszów
To obtain more detailed information, please contact:
Opella Healthcare Poland Sp. z o.o.
ul. Marcina Kasprzaka 6
01-211 Warsaw
Tel.: +48 22 280 00 00
Date of last revision of the leaflet:April 2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.